SCHEMBL10027285

SCHEMBL10027285

CCCCc1cnc2c(O)c(-c3ccc(F)cc3)ccn2c1=O

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ GCGR P47871 3/20 0.37
▸ APLNR P35414 7/20 0.35
▸ USP7 Q93009 1/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ ALDH1A1 P00352 2/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ ADORA3 P0DMS8 3/20 0.34
▸ ADORA2B P29275 1/20 0.34
▸ ADORA1 P30542 1/20 0.34
▸ ADORA2A P29274 1/20 0.34
▸ LTB4R Q15722 1/20 0.34
▸ LTB4R2 Q9NPC1 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ PTGS1 P23219 1/20 0.33
▸ PTGS2 P35354 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17808740 0.93 USP7 (0.36) GCGRUSP7NPC1CYP1A2CYP2C19
SCHEMBL10027286 0.87 DCTPP1 (0.42) APLNRALDH1A1ADORA3ADORA2BADORA1
SCHEMBL10027287 0.83 CYP3A4 (0.42) APLNRCYP1A2CYP2C9CYP2C19ADORA3
SCHEMBL17808760 0.83 LMNA (0.36) CYP1A2CYP2C9CYP2C19ALDH1A1
SCHEMBL17808764 0.80 PDE3B (0.36) USP7
SCHEMBL10027235 0.80 MAPT (0.36) CYP1A2ALDH1A1GAA
SCHEMBL17808844 0.79 TP53 (0.44) NPC1RAB9AALDH1A1
SCHEMBL10027290 0.79 SMARCA2 (0.46) GCGRAPLNRNPC1RAB9AALDH1A1
SCHEMBL17808756 0.77 PTGS1 (0.36) GCGRNPC1CYP1A2RAB9AALDH1A1
SCHEMBL17808792 0.77 CHEK1 (0.49) CYP2C19ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163760-B2 Use of pyridopyrimidine compounds in the treatment of gliomas PRANA BIOTECHNOLOGY LIMITED (AU) 2012-04-24 — — US disclosed
US-8163760-B2 Use of pyridopyrimidine compounds in the treatment of gliomas PRANA BIOTECHNOLOGY LIMITED (AU) 2012-04-24 — — US disclosed
US-20100069393-A1 METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME PRANA BIOTECHNOLOGY LIMITED (AU) 2010-03-18 — — US disclosed
US-20100069393-A1 METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME PRANA BIOTECHNOLOGY LIMITED (AU) 2010-03-18 — — US disclosed
WO-2007147217-A1 METHOD OF TREATMENT OF GLIOMA BRAIN TUMOUR PRANA BIOTECHNOLOGY LIMITED (AU) 2007-12-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069393-A1 METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME MGMT, DHFR, IDH2 GCGR 3247/4885APLNR 2524/4885USP7 3082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback